Toxic epidermal necrolysis in systemic lupus erythematosus

Horne, N.S.; Narayan, A.R.; Young, Rosemarie; Frieri, Marianne

doi:10.1016/j.autrev.2005.10.003

Cited by 41 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although most drug reactions are characterized by a rash that could be maculopapular, the most severe and lifethreatening drug reactions, such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have recently been associated with specific HLA alleles [10]. Certain drugs such as abacavir, aromatic anticonvulsants such as carbamazepine, and allopurinol have all been linked with severe drug reactions thought to be T-cell-mediated in patients with specific HLA alleles, namely HLA-B*5701, HLA-B*1502, and HLA-B*5801, respectively [11••].…”

Section: Drugsmentioning

confidence: 99%

Eosinophilic Disorders in Various Diseases

Celestin

Frieri

2011

Curr Allergy Asthma Rep

Self Cite

View full text Add to dashboard Cite

Peripheral and tissue eosinophilia are usually associated with a variety of inflammatory, malignant, and infectious conditions. As the presence of eosinophils in the tissues may cause significant cellular damage to vital organs such as the heart, tissue eosinophilia should be diagnosed and treated promptly. One operative way to evaluate eosinophilic disorders is to classify them into extrinsic and intrinsic. While extrinsic eosinophilic disorders are usually due to the production of eosinopoietic factors derived from T cells or tumor cells, the intrinsic types generally are the result of genetic mutations in the eosinophilic lineage. As we understand more the biology of eosinophils, only a few eosinophilic disorders remain idiopathic. The purpose of this article is to help the clinician classify in an operational manner most eosinophilic disorders, using the extrinsic and intrinsic model. This may facilitate not only a better understanding of the role of eosinophils in these disorders, but also help the systematic clinical work-up and potential treatment of affected patients.

show abstract

Section: Drugsmentioning

confidence: 99%

Eosinophilic Disorders in Various Diseases

Celestin

Frieri

2011

Curr Allergy Asthma Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Horne et al cuestionan que la NET por lupus sea una entidad diferente a la NET clásica medicamentosa (13). Es bien sabido que los pacientes con enfermedad del tejido conectivo tienen mayor riesgo de hacer NET medicamentosa y la gran mayoría están expuestos a múltiples medicamentos; por esto creen que NET por lupus no es una entidad diferente (14).…”

Section: Medicinaunclassified

“…En cuanto al tratamiento del lupus tipo NET, hay múltiples reportes de casos tratados con inmunoglobulina humana, similar al tratamiento de la NET clásica (9,12,13,19). Se cree que el mecanismo de acción de la inmunoglobulina es a través del bloqueo de la interacción Fas-Fas ligando (mediadora de la apoptosis) mediante anticuerpos (9,12,13).…”

Section: Medicinaunclassified

See 1 more Smart Citation

Necrólisis epidérmica tóxica y lupus eritematoso sistémico

Vélez¹,

Morales²,

Calle³

et al. 2018

CES Med.

View full text Add to dashboard Cite

Comparte ResumenEl lupus eritematoso sistémico con manifestación tipo necrólisis epidérmi-ca tóxica es una entidad descrita recientemente y cada vez aparecen más reportes en la literatura. Se describe el caso de una paciente de 15 años con lupus eritematoso sistémico quien presentó una necrólisis epidérmica tóxica extensa, cuyas lesiones iniciales eran tipo eritema multiforme. Se discute el caso a la luz de la literatura actual sobre esta nueva entidad.Palabras clave: Necrolisis epidérmica tóxica; Eritema multiforme; Síndrome de Stevens Johnson; Lupus eritematoso sistémico; Lupus eritematoso cutáneo. AbstractToxic epidermal necrolysis (TEN)-like systemic lupus erythematosus is a recently described entity and more cases are being published in the literature today. We describe the case of a 15-year old patient with systemic lupus erythematosus who developed TEN that initially started with erythema multiforme (EM)-like lesiones. We discuss this case according to the published literature on this new entity.Keywords: Toxic epidermal necrolysis; Erythema multiforme; Stevens-Johnson syndrome; Systemic lupus erythematosus; Cutaneous lupus erythematosus Caso clínicoSe trataba de una niña de 15 años, residente en el departamento de Antioquia, con un cuadro clínico de tres meses de evolución que consistía en edema progresivo de cara y los miembros inferiores, junto a disnea de medianos esfuerzos y artralgias con artritis de ambas manos. Lo anterior asociado a un cuadro de 15 días de evolución de un rash morbiliforme en áreas fotoexpuestas, muy pruriginoso, que posteriormente se generalizó. La paciente consultó a un hospital de segundo nivel de atención, en donde le encontraron, adicionalmente, cifras elevadas de presión arterial.La menor fue hospitalizada por el servicio de medicina Interna y se le inició manejo con esteroides tópicos y antihistamínicos y le fueron solicitados exámenes paraclínicos, que reportaron: Hb 7,2, leucocitos de 5 800 (81 % de neutrófilos y 12 % linfocitos), anti-SM y anti-ADN positivos, anticuerpos antinucleares (ANA´S) reactivos 1:320 con patrón moteado, anti-Ro y anti-La negativos, velocidad de sedimentación globular 60, creatinina 2,05,

show abstract

“…17 There is evidence that systemic lupus is a risk factor as well. 18 Although SJS can be caused by viral infections and malignancies, the main cause is medications. 6 SJS may be caused by vancomycin, allopurinol, valproate, levofl oxacin, diclofenac, etravirine, isotretinoin, fluconazole, 19 valdecoxib, sitagliptin, oseltamivir, penicillins, barbiturates, sulphonamides, phenytoin, azithromycin, oxcarbazepine, zonisamide, modafinil, 20 lamotrigine, nevirapine, pyrimethamine, ibuprofen, 21 ethosuximide, carbamazepine, bupropion, telaprevir 22 and nystatin.…”

mentioning

confidence: 99%